Jose Sarriera is an Oncology physician affiliated with Orlando Health. OpenAlex indexes 9 publications with 736 citations (h-index 2).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
6 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.1%Thalidomide Analog22.7%Revlimid57%Pomalyst43%Part D≥32 patientsKinase inhibitor17%Imbruvica55%Jakafi12%Tasigna11%Sprycel10%Brukinsa6%Imatinib Mesylate6%Part D<11 patients+ 5 more classes in this area
Dermatology
14.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.9%Acyclovir100%Part D≥48 patientsBlood & clotting
14.3%Factor Xa inhibitor13.1%Eliquis70%Xarelto30%Part D<11 patientsThrombopoietin Receptor Agonist1.2%Promacta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Inherited factor II deficiency with paradoxical hypercoagulability
Blood Coagulation & Fibrinolysis
2018 - Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM)
Journal of Clinical Oncology
2006
Similar KOLs
Other experts from the same institution or the same specialty.
Karoly Horvath, MD
Orlando Health
Alfredo Voloschin, MD
Orlando Health
Larry Fox, MD
Orlando Health
Sajeve Thomas, MD
Orlando Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”